Kronos Bio to Showcase Research at Key Medical Conferences
Kronos Bio to Showcase Research at Key Medical Conferences
Kronos Bio, Inc. (Nasdaq: KRON), a pioneering company in cancer treatment, is gearing up for an exciting series of conferences in the upcoming month. These events highlight their dedication to advancing small molecule therapeutics that target cancers driven by deregulated transcription. The involvement at these conferences not only signifies their commitment to research and innovation but also aims to share crucial advancements with the global medical community.
Upcoming Conferences
H.C. Wainwright 26th Annual Global Investment Conference
This esteemed conference will be held from September 9 to 11, where Kronos Bio’s President and CEO, Norbert Bischofberger, Ph.D., will present on September 9 at 2:30 p.m. ET. This provides an excellent opportunity for investors and stakeholders to grasp the company’s vision and clinical developments.
American Association for Cancer Research Ovarian Cancer Research Symposium
Scheduled for September 20-21, this symposium in Seattle will feature a presentation by Kronos Bio’s Director of Translational Development, Luis Carvajal, Ph.D. He will present a poster on his team's findings regarding KB-0742, which is an oral CDK9 inhibitor aimed at treating recurrent ovarian cancer. The session includes an author discussion where attendees can engage directly with the researcher.
International Myeloma Society Annual Meeting
From September 25 to 28, Kronos Bio will also be part of the International Myeloma Society's 21st Annual Meeting in Rio de Janeiro. Collaborator Mariateresa Fulciniti, Ph.D., is set to deliver an oral presentation exploring the effects of p300 catalytic inhibition on multiple myeloma cell growth. This session is crucial as it will provide insights into new therapeutic approaches for managing this type of cancer.
Webcast and Research Accessibility
Kronos Bio aims to maintain transparency and engagement with its audience by providing a live audio webcast of the H.C. Wainwright presentation. This can be accessed on the company’s website under the Investors & Media section, and it will remain available for replay for 30 days post-event. Furthermore, the research posters presented at these medical meetings will also be accessible on the Kronos Bio website, ensuring that stakeholders and interested parties can review the latest scientific advancements from the company.
About Kronos Bio
Kronos Bio, Inc. is at the forefront of cancer treatment, focusing on small molecule therapeutics that address transcriptional deregulation—an essential characteristic of cancerous cells. The company employs a unique discovery engine aimed at decoding complex transcription factor networks. This process helps in identifying druggable cofactors vital for tumor-specific conditions. Among their impressive line-up, Istisociclib (KB-0742) demonstrates a potent approach to combat MYC deregulation in solid tumors, while KB-9558 leverages p300 inhibition to target IRF4 dependence in multiple myeloma.
With a central office in San Mateo and a research facility in Cambridge, Kronos Bio is committed to driving innovation in oncological therapies. They invite all interested parties to learn more by visiting their website.
Frequently Asked Questions
What is Kronos Bio focused on?
Kronos Bio focuses on developing small molecule therapeutics for cancer treatment, particularly those related to deregulated transcription.
When is the H.C. Wainwright Conference?
The H.C. Wainwright 26th Annual Global Investment Conference is scheduled for September 9-11, 2024.
Who will present at the AACR Symposium?
At the AACR Symposium, Luis Carvajal, Ph.D., will present a poster regarding the clinical expansion of KB-0742.
How can I access the webcast of the presentation?
The live audio webcast of the H.C. Wainwright presentation will be available on the Kronos Bio website and can be replayed for 30 days afterward.
Is Kronos Bio involved in research collaborations?
Yes, Kronos Bio collaborates with institutions like the Dana-Farber Cancer Institute to enhance their research capabilities and findings.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Super Micro Computer Responds to Hindenburg's Allegations
- Equature's 2024.3 Software Revolutionizes Public Safety Operations
- Leinco Technologies Inc. Expands Portfolio with QED Biosciences
- Jamie Foxx Brings Humor to BetMGM's 2024 Football Campaign
- Wipfli Unveils 2024 Annual Report Detailing Growth and Innovation
- Autonomous Cars Forecast: Growth to USD 43.44 Billion By 2032
- Investing Insights: Nvidia Versus Arm Holdings in AI Sector
- Agmatix Unveils RegenIQ: Revolutionizing Regenerative Agriculture
- BoomerangFX Expands Innovative Solutions in Asia and Latin America
- Costco to Expand with Four New Locations by End of 2024
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- BCFNJC's What We Heard Report from First Nations Justice Forum
- Asia Pacific Wireless Earphones Market Expected to Thrive
- Cork Packaging Market Expected to Hit USD 2.7 Billion Growth
- MICE Industry Expected to Reach $1,337 Billion by 2033
- Packaging Automation Market Growth Driven by E-commerce Boom
- Status of Audit for Aktsiaselts Silvano Fashion Group Revealed
- Tiny Traveler Unveils Advanced AI Baby Monitor for Parents
- Portable Projector Market Growth Projections: $2.1 Billion by 2029
- Celebrate the Festive Season at The Ocean Club, Bahamas
- Ethical AI Transformation: The P&C Insurance Industry's Role
- HomeSafe Alliance Achieves Milestone Of 100 Military Moves
- Xiaohongshu's Street Life Festival Draws Record Attendance and Engagement
- Starlight Children's Foundation Celebrates Childhood Cancer Month
- Sandals Resorts Partners with Leo Burnett for Creative Vision
Recent Articles
- Super Micro Computer Responds to Hindenburg's Allegations
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- Cork Packaging Market Expected to Hit USD 2.7 Billion Growth
- Ethical AI Transformation: The P&C Insurance Industry's Role
- Concord Acquisition Corp II Considers Nasdaq Listing Following Delisting
- Exploring the Event Logistics Market Growth to USD 87.8 Billion
- UC Asset LP Announces Management-Driven Stock Buyback Plan
- Corporate Profit Challenges: Earnings Outlook for 2025
- Kraft Heinz: Long-Term Growth Potential in Consumer Staples
- Argonaut Gold's Redemption of Convertible Debentures Announced
- Park Street A/S Announces Significant Shareholding Changes
- Growing Demand for Pick to Light Solutions Transforming Industries
- Public Disclosure by Rathbones Group on Balanced Trust
- Veterinary Point of Care Diagnostics Market Forecast Growth
- Smart Elevator Market Expected to Reach $43.91 Billion by 2031
- Alexandria Real Estate Equities Announces Q3 2024 Results Call
- Rob Faw Unveils Leadership Strategies for Today's Challenges
- PDS Biotech CEO to Present at H.C. Wainwright Conference
- PyroGenesis Secures $1 Million Contract for Graphite Production
- GH Research Reports Q2 2024 Results and Business Progress
- Save Over £450 on Your Holiday Car Hire with Essential Tips
- Amazon's Stock Performance and Future Growth Potential
- AT&T Webcast with John Stankey: Insights from Goldman Sachs
- HSG Laser Celebrates Four Years of Innovation and Growth
- US Dollar Response to ISM Survey and Global Economic Factors